Skip To Main Content
Charidimos Tsagkas on Muck Rack

Charidimos Tsagkas

As seen in: Nature, Neurology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Charidimos

Contact Charidimos, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A pipeline to characterize spinal cord pathology in neurological disorders combining magnetic resonance microscopy and histopathology

|
By Charidimos Tsagkas, Maxime Donadieu, Roy Sun, Katherine Cameron, Stephen Dodd, Daniel S. Reich, Govind Nair, Brandon Bujak, Camille Rood
| Nature Verified
Abstract The length, shape, and size of the spinal cord (SC) present unique challenges for MRI, including the need for high resolution to distinguish anatomical and pathological features along its span. Postmortem MRI offers an opportunity to map SC tissue abnormalities and investigate their histological correlates. We developed a pipeline combining postmortem microscopic resolution MRI (MR microscopy; MRM) of whole formalin-fixed SC specimens with targeted histopathological analysis.
Open in Who Shared Issue with article?

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment

|
By Martin Diebold, Neurologic Clinic, Bettina Fischer-Barnicol, Charidimos Tsagkas
| Neurology Verified
Abstract Objective To test whether patients with MS on disease-modifying treatments (DMTs) are at a higher risk of acute or chronic hepatitis E virus (HEV) infections or extrahepatic manifestations, we monitored approximately 1,100 persons with MS (pwMS) during 3 years for HEV infection. Methods This is an observational case series study. All pwMS were followed in our MS center between January 2016 and December 2018 with at least annual standardized clinical and laboratory assessments.
Open in Who Shared Issue with article?
See all 2 articles